Latest news with #Wegovy
&w=3840&q=100)
Business Standard
32 minutes ago
- Health
- Business Standard
India's response to obesity drug Mounjaro 'positive', says Eli Lilly
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The US-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May, according to data from research firm PharmaTrac. With its mass-market pricing, Mounjaro could become a mainstay in obesity and diabetes management in India, PharmaTrac said. The global demand for Lilly's Mounjaro and Novo's version Wegovy has skyrocketed in the last few years, even leading to shortages in a few countries, including the US. "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said on Thursday. Obesity and diabetes rates have been steadily climbing in India. A government survey conducted between 2019 and 2021 showed 24 per cent of women and nearly 23 per cent of men aged 15 to 49 were overweight or obese, up from 20.6 per cent and 19 per cent, respectively, in 2015-2016. In addition, the number of adults with diabetes is projected to increase to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation. Indian drugmakers are now racing to develop cheaper versions of the weight-loss drugs to grab a share of the market estimated to be around $150 billion by the early 2030s. Semaglutide, the active ingredient in Wegovy, is likely to go off-patent in 2026 in India. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
2 hours ago
- Health
- Time of India
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May, according to data from research firm PharmaTrac. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like An engineer reveals: 1 simple trick to get all TV channels Techno Mag Learn More Undo With its mass-market pricing, Mounjaro could become a mainstay in obesity and diabetes management in India, PharmaTrac said. The global demand for Lilly's Mounjaro and Novo's version Wegovy has skyrocketed in the last few years, even leading to shortages in a few countries, including the U.S. Live Events "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said on Thursday. Obesity and diabetes rates have been steadily climbing in India. A government survey conducted between 2019 and 2021 showed 24% of women and nearly 23% of men aged 15 to 49 were overweight or obese, up from 20.6% and 19%, respectively, in 2015-2016. In addition, the number of adults with diabetes is projected to increase to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation. Indian drugmakers are now racing to develop cheaper versions of the weight-loss drugs to grab a share of the market estimated to be around $150 billion by the early 2030s. Semaglutide, the active ingredient in Wegovy, is likely to go off-patent in 2026 in India.
Telegraph
6 hours ago
- Health
- Telegraph
Cancer patients warned not to use weight-loss jabs
Cancer patients should not take 'quick fix' weight-loss jabs unless under specialist care, experts have warned. Macmillan Cancer Support said there had been a surge in people asking about the drugs, such as Wegovy and Mounjaro, but that there was not enough evidence about how they might affect cancer treatment. It said there was already evidence the injections may affect how other medicines are absorbed by the body, and that this could include cancer drugs. The manufacturers acknowledge the weight-loss jabs may affect the absorption of other drugs. The contraceptive pill and hormone replacement therapy (HRT) are among treatments experts have said are affected when taken orally. It is thought the mechanism by which the drugs make a person feel fuller and reduce their appetite – called delayed gastric emptying – also slows down the rate at which medicines are absorbed by the gut. Dr Owen Carter, national clinical adviser at Macmillan Cancer Support, said there had been 'a noticeable increase in calls to Macmillan's free support line and a flurry of messages on our peer-to-peer online community about weight-loss drugs'. 'We know that cancer affects everybody differently and it's understandable that lots of people are interested in new drugs which accelerate weight loss, particularly if they want to manage their weight before or after treatment for cancer,' he said. 'While 'quick fixes' may seem attractive, we simply do not know enough about the long-term impact of these weight-loss medications to recommend them if they're not prescribed by a specialist.' He also said that 'certain weight-loss medications carry warnings about a potential link with thyroid cancer'. He added that 'eating well and staying as active as possible are proven to help people feel better, increase their energy levels and strengthen their immune systems, which can help them to manage their weight and cope better with cancer treatment'. Weight-loss drugs have been available on the NHS to a select few patients via specialist weight management clinics. The majority of the estimated 1.5 million people taking the drugs in the UK are accessing them privately for around £200 a month, often from online pharmacies. Later this month, GPs will be able to prescribe one of the drugs, Mounjaro, to obese patients. Last week, Prof Sir Stephen Powis, the NHS England national medical director, said they could be as transformative as statins.
Miami Herald
a day ago
- Business
- Miami Herald
WeightWatchers takes drastic step to exit bankruptcy
Growing up, I always knew when it was "weigh-in day." My mom would slip into the kitchen in the early morning and emerge with her little tracker notebook tucked under one arm and a low-point snack in the other. I was fascinated. She had little bars in shiny wrappers, chocolate-covered pretzels that somehow counted as healthy, and a whole drawer of food labeled with blue and purple stickers. I remember trying some of her WeightWatchers snacks and being surprised by how much I liked them. Related: How psychedelic mushrooms are helping people unlock their potential WeightWatchers was more than just a diet brand back then. It was a community. An identity. It was built on accountability and structure and a little bit of ritual. So it's strange, now, to see the brand struggling. For years, it's faced declining membership, shifting trends, and fierce competition from newer, tech-driven health platforms. And while the company has tried to modernize by adding app integrations, personalized plans, and even embracing controversial GLP-1 medications-it hasn't been enough to avoid serious financial trouble. Now, the brand is making its biggest move yet. On June 17, WeightWatchers announced a major milestone: the court just greenlit its Plan of Reorganization. That means the company is finally on track to exit bankruptcy-potentially as soon as next week. Under the new plan, WeightWatchers is wiping out $1.15 billion in debt. That's more than 70% of what it owed, and it gives the brand a much-needed shot at stability. Here's what that looks like: lenders and noteholders are trading their claims for new loans and equity. Related: This new AI tool could change how you shop for makeup Existing shareholders? They're getting just 9% of the new company. A brutal haircut, but one that clears the path forward. CEO Tara Comonte called it a "meaningful turning point" and said the company is doubling down on what's next: focusing on lifestyle change, clinical care, and yes, GLP-1 medications like Ozempic and Wegovy. Through it all, the company stayed public. Now, with the paperwork nearly finalized, it's hoping to emerge with more speed, less baggage, and a clear runway to grow again. Let's be hasn't been the go-to name in weight loss for a while. Once the gold standard, it's been losing ground to flashier, tech-savvy rivals like Noom, MyFitnessPal, and a wave of telehealth startups pushing the latest miracle meds. But instead of fighting the shift, WW leaned in. It bought Sequence, a GLP-1 prescription platform, and started blending its old-school accountability model with medical support. Smart move, but an expensive one. Revenues fell, debt climbed, and the stock tanked. This bankruptcy reset? It might be the company's best shot at surviving the wellness wars. With over a billion in debt erased, the brand can finally focus on fixing what matters: modernizing the product, rebuilding trust, and reaching people in a crowded, noisy market. The trick will be walking the line between old and new. Between nostalgic snack bars and doctor-prescribed injections. But if WW gets it right, it won't just be a comeback. It'll be a transformation. And for the millions who once counted points and tracked progress, it might even feel like coming home. Related: Stanley cup maker sparks criticism over controversial partnership The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Glasgow Times
a day ago
- Health
- Glasgow Times
UK Mounjaro warning issued ahead of heatwave temperatures
It's estimated that around 1.5 million Brits are now taking weight-loss drugs, with numbers increasing each week. The last year has seen a huge increase in the number of people taking GLP-1 receptor agonists, some prescribed by the NHS and others by private doctors, with common injectibles including semaglutide (Wegovy and Ozempic), tirzepatide (Mounjaro) and liraglutide (Saxenda). As the temperatures rise, experts are stressing that users must store weight loss injections in a refrigerator (2-8°C or 36-46°F), especially after starting the course. Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: — We are Primary Care (@PrimaryCareNHS) June 12, 2025 'Weight loss injections can be adversely affected by hot weather, particularly regarding storage and stability," says James O'Loan, obesity specialist and weight loss injection expert at pharmacists Chemist4U. "Understanding the storage instructions when using any prescribed medication is vital to keep it in optimal condition. "Although weight loss injections can be stored at room temperature for up to 30 days (some injections are 42 days, so always check with your prescriber or refer to the patient information leaflet), this is only provided the temperature does not exceed 30°C. During hot weather, and to be on the safe side, it is always best to keep your weight loss injections refrigerated if you're able." Can I take my Mounjaro pen on holiday? The advice for the UK heatwave is also also worth noting for those heading on holiday or travelling during the warmer weather. However, if you're flying, remember to pack your injections in your carry-on since the baggage hold on a plane can plummet to below-freezing temperatures. Finding the right temperature for your pen is important: not too hot or too cold. If you inject after incorrectly storing your pen, it might not be safe for use. How do I know if my Mounjaro pen is safe to use? "There are a few important things to consider when checking if your weight loss pen is safe to use," says James. "Inspect the pen to ensure it is not damaged and the medicine inside is clear, with no particles or cloudiness. The liquid should be colourless or slightly yellow. If you have left your pen unrefrigerated during hot weather and are unsure whether it is still safe to use, always consult your prescriber before injecting. "Staying hydrated whilst taking weight loss injections is key. Weight loss injections can cause side effects such as nausea, constipation, diarrhoea and dizziness, which, without sufficient fluids, can lead to dehydration. "We recommend drinking plenty of water throughout the day, even when you're not thirsty. If experiencing diarrhoea or vomiting, try using electrolyte drinks, rehydrate quickly and apply sunscreen whenever you are outdoors. This will help those who suffer from heightened sensitivity to UV rays.' Do you need to tell your travel insurance you are taking Mounjaro? Yes. Travel insurance providers are warning that the growing number of Brits turning to these breakthrough drugs for weight management could lose their cover and face huge medical bills abroad if they don't declare their usage when arranging travel insurance. Many don't want to admit they are taking the weight-loss drugs, or think that if they buy it privately, it doesn't need to be declared. Niraj Mamtora, director at Forum Insurance, says: 'Weight-loss medications like Ozempic are transforming lives across the UK, but too many travellers don't realise the insurance implications. If you're using these drugs, you must declare both the medication and the condition it's prescribed for. 'Failure to do so is not a minor oversight - it's a serious breach of your travel insurance contract. If you need medical help overseas and haven't declared your medication, your claim can be refused and your policy cancelled. The financial consequences can be severe.' Recommended reading: What happens if you don't disclose weight-loss jabs on your travel insurance? 'Non-disclosure is a gamble that's simply not worth taking," says Niraj. "If you don't declare your medication or the underlying condition, your insurer is within their rights to refuse any claim, even if it seems unrelated. 'Many travellers only discover too late that their travel insurance claims are rejected, leaving them without support and facing potentially huge bills. "With the average medical claim abroad now exceeding £1,700, and costs rising significantly with age, being properly covered is more important than ever.' Insurance claims related to undeclared conditions or medications can be refused, even if the issue seems unrelated.
